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Abstract 
Background: The prevalence of lipodystrophy ranges from 31 to 65%, depending on the criteria adopted for 
diagnosis. The usual methods applied in the diagnosis vary from self‑perception, medical examination, skinfolds 
measurements, or even imaging assessment for confirmation of fat distribution changes. Although several methods 
have been developed, there is no gold standard for characterization of LA and LH, or mixed forms. This study aimed to 
compare self‑reported signs of lipodystrophy with objective measures by skinfolds and circumferences, and to evalu‑
ate the prevalence of lipoatrophy (LA) and lipohypertrophy (LH) among subjects living with HIV/AIDS on ART.
Methods: A cross‑sectional study enrolled participants living with HIV/AIDS receiving ART, aged 18 years or older 
from an outpatient health care center, in Southern Brazil. Self‑reported body fat enlargement in the abdomen, chest 
or breasts, and dorsocervical fat pad were used to determine LH, while LA was identified by self‑reported fat wasting 
of the face, neck, legs, arms or buttocks. Measurements were obtained with a scientific caliper for infraorbital, buccal, 
and submandibular skinfolds, and using an inelastic tape to measure circumferences of waist, hip, neck, and arm. LH 
and LA were established by the presence of at least one self‑reported sign.
Results: Comparisons of self‑reported signs with objective measurements for men and women were carried out in 
815 participants on ART, out of 1240 participants with HIV infection. Self‑report of decreased facial fat and sunken 
cheeks was associated with lower infraorbital, buccal, and submandibular skinfolds. Participants who reported buffalo 
hump had, on average, greater neck circumference, as well as those who have increased waist circumference also 
reported abdominal enlargement, but no buttock wasting. Men were most commonly affected by lipoatrophy (73 vs. 
53%; P < 0.001), and women by lipohypertrophy (79 vs. 56%; P < 0.001).
Conclusion: In conclusion, self‑reported signs of lipodystrophy and lipoatrophy are prevalent, differ by gender, and 
are associated with objective measurements in people living with HIV/AIDS.
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Background
Highly active antiretroviral therapy (HAART) has 
increased the survival and quality of life of people liv-
ing with HIV/AIDS. However, the use of antiretroviral 
therapy (ART) is associated with metabolic abnormali-
ties, including increased serum lipids, glucose, and insu-
lin resistance. Combined, these disorders represent an 
atherogenic profile, increasing the risk of developing car-
diovascular disease [1]. The interaction of host factors, 
HIV, and HAART leads to the accumulation and loss of 
body fat in specific body sites [2], which has been identi-
fied as lipodystrophy [3]. Lipodystrophy includes periph-
eral subcutaneous fat loss (lipoatrophy; LA) in the upper 
and lower limbs, buttocks, and face as well as increased 
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body fat, (lipohypertrophy; LH) detected as abdominal 
visceral fat accumulation, dorsocervical fat pad (buffalo 
hump), and chest or breast enlargement. LA and LH can 
be presented separately or in combination in the same 
participant (mixed forms) [4].
The prevalence of lipodystrophy ranges from 31 to 65% 
[5–11] depending on the criteria adopted for diagnosis. 
The usual methods applied in the diagnosis vary from 
self-perception [6, 12], health professional [12] or physi-
cal examination [7], skinfolds measurements [8], or even 
imaging assessment such as dual emission X-ray absorp-
tiometry (DEXA) [7, 9], CT [9], or MRI [10] for confir-
mation of fat distribution changes [10, 11]. Although 
several methods have been developed, there is no gold 
standard for characterization of LA and LH, or mixed 
forms [2, 13]. A multicenter case–control study was 
designed to develop a sensitive, specific, and broadly 
applicable definition of lipodystrophy for people living 
with HIV, providing a model with a reduced number of 
variables. The model included clinical data as age, dura-
tion of HIV infection, HIV disease clinical stage, change 
in CD4+ count from nadir, and waist circumference [9]. 
This model was improved by a neural network analysis 
with an input of a large set of variables. The neural net-
work model was 72% accuracy (72% sensitivity and 71% 
specificity), compared with 68% (73% sensitivity and 
63% specificity) of the first one [14]. However, the mod-
els have not been used in clinical practice. One of them 
requires expensive imaging exams, as well as large num-
ber of variables [14] and they were not incorporated in 
the routine diagnosis of lipodystrophy.
The diagnostic approach most commonly used to 
detect lipodystrophy is self-report of specific changes in 
body fat distribution [15, 16]. Physicians detect LA or 
LH signs during clinical examination [6], but changes in 
body fat depends on repeated observations though con-
tinuous care of patients by the same doctor [15]. A few 
studies require both patient and doctor agreement on 
signs of lipodystrophy [15, 17]. Few scales have attempted 
to quantify the intensity of body fat alterations to com-
pute an overall score [17–19]. However, the comparison 
between self-reported signs and objective measurements 
through skinfolds and circumferences is lacking. There-
fore, this study aimed to compare self-reported signs of 
lipodystrophy: LA and LH with objective measurements 
of skinfolds and circumferences. In addition, this study 
also aimed to compare prevalence of LA and LH between 
men and women living with HIV on ARV.
Methods
This cross-sectional study enrolled a consecutive sample 
of men and women living with HIV/AIDS on ART, from 
June 2006 to December 2008. Participants aged 18 years 
or older, who consecutively sought HIV diagnostic con-
firmation or treatment at the HIV/AIDS outpatient 
care center in Southern Brazil and were invited to par-
ticipate. Pregnant women, intellectually impaired partici-
pants, and incarcerated or institutionalized persons were 
excluded. The outpatient care center—Hospital Sanatorio 
Partenon—is one of three larger centers, which provide 
AIDS Care and Treatment for patients living in any area 
of the metropolitan area.
Study variables
A standardized questionnaire was used to collect data on 
demographic and socioeconomic characteristics [20], and 
another questionnaire to obtain data on use of antiretro-
viral drugs and signs of lipodystrophy [21] among other 
variables. Race was self-reported and categorized as Cau-
casian or non-Caucasian. Education was determined as 
the number of years at school, as a socioeconomic status 
proxy. Highly active antiretroviral therapy was defined as 
the use of three or more drugs over the 12 months pre-
ceding the interview. Body changes were assessed, both 
subjectively (by report) and objectively (by examination). 
Changes in body fat were classified as reduced, increased 
or none.
Lipodystrophy was defined as the self-perception of 
changes in body fat distribution through questions about 
changes in specific regions, such as face (hollow cheeks, 
double chin); neck (enlargement and/or buffalo hump); 
chest (or breasts) and abdomen enlargement; arms, fore-
arms, hands, thighs, legs and feet (muscular arms and 
legs, prominent superficial veins); hips and/or buttocks 
wasting. The question about presence of double chin 
was used to capture the perception of increased fat in 
the participant’s face and for internal consistency as well. 
The questions about neck enlargement and buffalo hump 
aimed to detect the accumulation of fat in the dorsocer-
vical spine, but they represent the same sign.
Lipohypertrophy was assessed by the accumulation of 
fat in the abdomen, chest or breasts, and dorsocervical 
region. Lipoatrophy was determined by the fat wasting of 
face, neck, legs, arms, and buttocks. Lipohypertrophy and 
lipoatrophy were established by the presence of at least 
one self-reported sign [11, 21] of hypertrophy or atrophy. 
Mixed lipodystrophy was diagnosed by the simultane-
ous presence of atrophic and hypertrophic changes [22]. 
Objective measurements of skinfolds were measured 
with a scientific calipers in the infraorbital, buccal, and 
submandibular regions, and using an inelastic tape to 
measure waist, hip, neck, and arm circumferences.
Data collection
Physicians and research assistants conducted standardized 
interviews, but only physicians measured blood pressure and 
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anthropometric parameters. Approximately 5% of interviews 
were repeated, by an independent researcher, for quality 
control purpose. Participants underwent laboratory testing 
(blood chemistry, viral load measurement, and CD4 counts), 
using standard techniques. Weight (kg) and height (m) were 
measured, with participants in barefoot and wearing light 
clothes, and body mass index (BMI) was calculated by divid-
ing weight (kg) by height (in m2). Waist circumference was 
measured midway between the uppermost border of the 
iliac crest and the lower border of the costal margin (rib cage) 
[23]. Hip circumference was measured at the greater tro-
chanter and the point of greatest gluteal protuberance. Neck 
circumference was measured 2 cm below the cricoid carti-
lage, while arm circumference was assessed at the midpoint 
between the acromion and olecranon. A flexible inelastic 
tape was employed to perform circumference measurements 
in triplicate. Facial skinfolds were measured with scientific 
skinfold calipers in the infraorbital, buccal, and subman-
dibular regions [24], by a physician who attended a session 
on AIDS Clinical Trials Group: Anthropometric Measure-
ment Training, in which the protocol used in this study was 
standardized. Before the start of the study, we confirmed the 
reproducibility in a few participants. Skinfold thicknesses 
were measured in duplicate. The average was calculated for 
all measurements carried out in duplicate or triplicate.
Calculation of sample size and statistical analysis
To detect a prevalence of lipohypertrophy between 6 and 
8%, with a 2% error and a confidence interval of 95%, the 
required sample size varied from 445 to 772 participants 
on ART. A sample of 778–1000 participants would be 
sufficient to detect a 9% difference in the prevalence of 
lipodystrophy between men and women, with a P value 
of 0.05, 80% statistical power, and a male-to-female ratio 
of 1:1. A total of 1240 participants were investigated and 
815 on ART were analyzed. The sample size was calcu-
lated using Epi Info™ version 3.4.1 (US Centers for Dis-
ease Control and Prevention, Atlanta, GA).
The prevalence of lipodystrophy between men and 
women was analyzed using Pearson’s Chi squared test or 
analysis of variance (ANOVA) for comparison of means. 
Among the self-reported characteristics of body fat dis-
tribution, we selected those that could be used to char-
acterize lipodystrophy, lipoatrophy and lipohypertrophy 
through their association with objective measurements 
of the corresponding body regions. All analyses were per-
formed in the Statistical Package for the Social Sciences 
(SPSS®) version 16 (Chicago, IL, United States).
Results
Among 1295 HIV-infected subjects, 1240 were enrolled, 
15 refused to take part, and 40 were excluded due to 
pregnancy, intellectual disability for signing a consent 
form, be incarcerated or institutionalized. Approximately 
a third of the participants were ARV naïve, therefore, the 
analysis was focused on 815 ART participants. As Table 1 
shows, men were older, had higher number of years at 
school, were predominantly Caucasians, and had lived 
longer with HIV/AIDS. Women had higher body mass 
index, but there was no gender difference in CD4 cell 
counts and undetectable viral load. Approximately 65% 
of women versus half of men were on protease inhibi-
tor (PI), but no association with gender was observed 
for thymidine analogue nucleoside reverse transcriptase 
inhibitors (tNRTI) (P = 0.9).
Figure  1 describes the means and standard devia-
tions of skinfolds measures according to self-perceived 
changes of decreased body fat distribution in the face. 
Self-reported signs of LA were associated with decreased 
infraorbital, buccal, and submandibular skinfolds.
Figure  2 shows means and standard deviations of cir-
cumference measurements for several body areas. Self-
reported signs of LH were associated with increased 
neck, arm, waist and hip circumferences. Participants 
who reported buffalo hump had an average of neck cir-
cumference higher than those who did not report. A 
reduced arm circumference was associated with the self-
report of superficial prominent veins. There was a strong 
association between increased waist circumference 
and self-reported signs of increased fat and abdominal 
enlargement; while buttock wasting was inversely associ-
ated with the average hip circumference.
Table 2 shows the prevalence of self-reported changes 
in body fat distribution for lipoatrophy and lipohyper-
trophy in men and women. There were significant differ-
ences for all self-perceived signs, including the number 
of reported signs. Men had higher prevalence of fat facial 
wasting, hollow cheeks, arm wasting, and prominent 
veins in the arms. Approximately two-thirds of women 
have reported abdominal enlargement or abdominal fat. 
It is noteworthy that 31% of men reported three or more 
lipoatrophy signs, making it difficult not notice. On the 
other side, only 12% of women had three signs of LH. 
Most participants on ART have LA or LH, with the for-
mer being more prevalent among men and the latter in 
women. Figure 3 shows that lipoatrophy was highly prev-
alent among those on tNRTI, but there was no associa-
tion between PI and lipohypertrophy.
Discussion
This study identified self-reported signs of LA and LH 
in 815 participants on ART that were significantly asso-
ciated with objective measures used to evaluate the fat 
redistribution. LA signs of facial fat wasting and hol-
low cheeks were associated with lower infraorbital, buc-
cal and submandibular skinfold. On the other hand, LH 
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signs were associated with increased circumferences 
such as abdomen enlargement detected by increased 
waist circumference and buffalo hump by larger neck cir-
cumference. Prevalence of lipoatrophy was more preva-
lent in men and lipohypertrophy in women. Although 
the differences between men and women do not consti-
tute formal validation test, comparative analysis of self-
reported signs of changes in body fat distribution with 
specific measurements supports the use of the former in 
clinical practice.
The use of skinfold or circumference measurements 
is more objective than clinical observation, but is lim-
ited by the absence of cutoffs for facial skinfolds, for 
instance [22]. Circumference cutoff points, which have 
been defined for other conditions, also require specific 
validation as predictors of HIV-associated lipodystro-
phy. The prevalence of lipodystrophy in this study was 
greater than that detected in a dynamic cohort of ambu-
latory patients from seven cities in the US [18]. In the US 
study, 4% of participants had moderate to severe signs 
of LH and 18% LA signs. In this study, prevalence rates 
were higher than those observed in a cross-sectional 
study conducted in São Paulo, Brazil, where 37% of par-
ticipants had LH, 49% LA, and 22% mixed lipodystro-
phy [25]. Although our and that study of São Paulo used 
the same criteria to classify changes in fat distribution, 
in the latter at about 10% of participants used tNRTI 
for more than 36  months versus one-third using it for 
4.5 years or more in our study. In this sense, the present 
study showed different manifestations of LA and LH 
when comparing men and women. Similarly to previous 
studies, our results suggest that increase in fat distribu-
tion in regions of the body were slightly more frequent 
in the women than men [22, 25]. In addition, our results 
were confirmatory for the differences between men and 
women in the prevalence of LA and LH. The finding 
that lipoatrophy was more prevalent among men [26] 








Age (years) 40.0 ± 9.7 41.5 ± 9.7 38.4 ± 10.1 <0.001
Caucasian ethnicity 457 (56.1) 380 (60.5) 312 (51.0) <0.001
Years of formal education 7.4 ± 4.1 8.0 ± 4.2 6.8 ± 3.8 <0.001
Body mass index (kg/m2) 24.6 ± 4.3 24.0 ± 3.5 25.3 ± 5.0 <0.001
Time since HIV diagnosis (years) 6.0 ± 4.2 6.3 ± 4.5 5.7 ± 3.9 0.03
CD4 (cells per μL) 0.3
 >350 451 (55.6) 221 (53.0) 230 (58.4)
 200–350 215 (26.5) 116 (27.8) 99 (25.1)
 <200 145 (17.9) 80 (19.2) 65 (16.5)
Viral load <50 copies/mL 488 (60.3) 261 (62.7) 227 (57.8) 0.15
Protease inhibitors use (PI) 468 (37.7) 212 (50.5) 256 (64.8) <0.001
Thymidine analogue nucleoside reverse transcriptase inhibitors (tNRTI) 253 (31.0) 131 (31.2) 122 (30.9) 0.9
Duration of PI (≥5 years) 105 (12.9) 61 (14.5) 44 (11.1) 0.15
Duration of tNRTI (≥4.5 years) 255 (31.3) 145 (34.5) 110 (27.8) 0.04
Fig. 1 Face: self‑perception changes vs. skinfold measurements 
(mean ± SD)
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and lipohypertrophy among women [27, 28] has been 
observed in other studies that used different fat distri-
bution assessments. Our study also confirmed previous 
results showing higher prevalence of lipoatrophy among 
participants who have used tNRTI [29].
This study identified high rates of self-reported signs of 
lipodystrophy, which were significantly associated with 
objective measurements. The number of self-reported 
signs and objective measures used to establish abnormal-
ity used herein was arbitrary, but was more conservative 
than those adopted in previous studies. The number of 
self-reported signs differed significantly between men 
and women.
Among the study limitations is the inability to com-
pare self-report signs with a reference standard for skin 
folds and circumferences. The establishment of cutoffs 
for skinfold and circumferences would make easier to 
identify LA and LH. However, this is the case of clinical 
practice in resource-limited settings [30]. In developing 
countries, access to quantification of regional fat with 
DEXA, computed tomography, or magnetic resonance 
imaging [7, 31]. is limited and does not cover assessment 
of lipodystrophy. The implementation of standardized 
criteria for the diagnosis of LA and LH in people living 
with HIV can provide relevant data to detect this condi-
tion and to compare results across studies.
Fig. 2 Fat body distribution: self‑reported changes vs. circumference measurements (mean ± SD)
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Reported signs of lipoatrophy
 Fat facial wasting 32.6 38.3 26.6 <0.001
 Hollow cheeks 31.2 36.9 25.1 <0.001
 Buttock wasting 30.9 33.8 27.8 0.07
 Arm wasting 24.5 30.7 18.0 <0.001
 Prominent veins in the arms 30.3 41.7 18.2 <0.001
Number of reported signs of lipoatrophy <0.001
 0 36.8 26.9 47.3
 1 23.1 24.0 22.0
 2 14.2 17.6 10.6
 ≥3 25.9 31.4 20.0
Reported signs of lipohypertrophy
 Buffalo hump 10.6 6.2 15.2 <0.001
 Increased abdominal fat 57.8 48.3 67.8 <0.001
 Abdominal enlargement 53.3 40.5 66.8 <0.001
Number of reported signs of lipohypertrophy <0.001
 0 33.3 44.5 21.3
 1 19.1 19.0 19.2
 2 40.4 33.3 47.8
 3 7.2 3.1 11.6
Prevalence of at least one reported sign
 Lipoatrophy 515 (63.2) 307 (73.1) 208 (52.7) <0.001
 Lipohypertrophy 544 (66.7) 233 (55.5) 311 (78.7) <0.001
Fig. 3 Prevalence of lipoatrophy and lipohypertrophy by use of PI and tNRTI
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Conclusion
In conclusion, self-reported signs of lipodystrophy and 
lipoatrophy are prevalent, differ by gender, and are asso-
ciated with objective measurements among HIV-infected 
adults receiving ART. Therefore, the use of subjective 
allows the detection of lipoatrophy and lipohypertrophy, 
but objective measures allow their quantification.
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